8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                   ----------


                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 Or 15(D) of The
                         Securities Exchange Act of 1934

        Date of report (Date of earliest event reported): April 28, 2003



                              ANTARES PHARMA, INC.
               --------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)


           Minnesota                 0-20945              41-1350192
  ----------------------------     ------------       -------------------
  (State or Other Jurisdiction     (Commission         (I.R.S. Employer
       of Incorporation)           File Number)       Identification No.)



            707 Eagleview Boulevard, Suite 414, Exton, PA       19341
- -------------------------------------------------------------------------------
              (Address of Principal Executive Offices)        (Zip Code)


       Registrant's telephone number, including area code: (610) 458-6200


                                 Not Applicable
- -------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)



Item 5.  Other Events and Required FD Disclsoure.

         On May 1, 2003, Antares Pharma, Inc. (the "Company") announced that the
Listing Qualifications arm of The Nasdaq Stock Market, Inc. had determined to
delist the Company's shares of common stock from trading on The Nasdaq SmallCap
Market effective May 7, 2003. The Company has requested an oral hearing with the
Listing Qualifications Panel to appeal Nasdaq's determination. This hearing
request will stay the delisting of the Company's common stock pending the
Panel's decision.

         A copy of the press release issued by the Company on May 1, 2003 is
attached hereto as Exhibit 99.1

Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.

(c)      Exhibits.

         99.1     Press Release dated May 1, 2003.




                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date: May 1, 2003                          ANTARES PHARMA, INC.



                                           By  /s/ Lawrence M. Christian
                                               ---------------------------
                                               Lawrence M. Christian
                                               Chief Financial Officer



                                  EXHIBIT INDEX

        99.1    Press Release dated May 1, 2003.

EX-99.1

                                                                    EXHIBIT 99.1

[LOGO]

Contact Information
Dr. Roger Harrison        CEO and President                      (610) 458-6200
Lawrence M. Christian     CFO and Vice President - Finance       (610) 458-6200
Jay M. Green              Managing Director, Duncan Capital      (212) 581-5150



              ANTARES PHARMA ANNOUNCES NASDAQ DELISTING NOTICE AND
                        COMPANY'S APPEAL OF SUCH ACTION

Exton, Pennsylvania - May 1, 2003 - Antares Pharma, Inc. (Nasdaq: ANTR) today
announced that it has received a notice from the Nasdaq Listing Qualifications
Staff indicating that the Company fails to comply with the stockholders' equity
requirements for continued listing set forth in Marketplace Rule 4310(c)(2)(B)
and indicating Nasdaq's intent to delist the Company's common stock from the
Nasdaq SmallCap Market effective at the opening of business on May 7, 2003. The
Company has appealed Nasdaq's determination by requesting an oral hearing before
the Nasdaq Listing Qualifications Panel. This hearing request will stay the
delisting of the Company's common stock pending the Listing Qualifications
Panel's decision.

About Antares Pharma
     Antares Pharma develops pharmaceutical delivery systems, including
needle-free and mini-needle injector systems and transdermal gel technologies.
These delivery systems improve both the efficiency of drug therapies and the
patient's quality of life. The Company's needle-free injection systems are
currently available in more than 20 countries. In addition, Antares Pharma has
several products under development and is conducting ongoing research to create
new products that combine various elements of the Company's technology
portfolio. Antares Pharma has corporate headquarters in Exton, Pennsylvania,
with research and development facilities in Minneapolis, Minnesota, and Basel,
Switzerland.

     Statements included in this press release that are not historical in nature
are "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Antares Pharma cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which
could cause actual results to differ materially and which are identified from
time to time in Antares Pharma's reports filed with the U.S. Securities and
Exchange Commission. Antares Pharma claims the



protection of the Safe Harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995.

         For more information, visit Antares Pharma's web site at
www.antarespharma.com.
- ---------------------

         Information included on Antares Pharma's website is not incorporated
herein by reference or otherwise.